Douglas M. McCarty

4.9k total citations · 1 hit paper
59 papers, 3.9k citations indexed

About

Douglas M. McCarty is a scholar working on Genetics, Molecular Biology and Physiology. According to data from OpenAlex, Douglas M. McCarty has authored 59 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Genetics, 30 papers in Molecular Biology and 20 papers in Physiology. Recurrent topics in Douglas M. McCarty's work include Virus-based gene therapy research (34 papers), Lysosomal Storage Disorders Research (19 papers) and RNA Interference and Gene Delivery (15 papers). Douglas M. McCarty is often cited by papers focused on Virus-based gene therapy research (34 papers), Lysosomal Storage Disorders Research (19 papers) and RNA Interference and Gene Delivery (15 papers). Douglas M. McCarty collaborates with scholars based in United States, France and Germany. Douglas M. McCarty's co-authors include R. Jude Samulski, Haiyan Fu, Samuel Young, Vivian W. Choi, Julianne DiRosario, Charles E. Toulson, Pooja Naik, Paul E. Monahan, Kimberly Zaraspe and Joseph Muenzer and has published in prestigious journals such as Nucleic Acids Research, Nature Medicine and PLoS ONE.

In The Last Decade

Douglas M. McCarty

58 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluating the state of the science for adeno-associated virus integration: An integrated perspective

2022 128 citations Guangping Gao, Douglas M. McCarty et al. Molecular Therapy profile →

Peers

Douglas M. McCarty

GENET

PHYSI

EPIDE

ONCOL

Cathryn Mah United States

Philippe Moullier France

Peter Bell United States

Irene Zolotukhin United States

Sandra Afione United States

Melissa A. Rosenfeld United States

Xiao Xiao United States

Joseph E. Rabinowitz United States

Christian Hinderer United States

R. Scott McIvor United States

Cathryn Mah United States

Douglas M. McCarty

2.2k ×0.9

2.0k ×0.8

GENET

610 ×0.9

PHYSI

359 ×0.6

EPIDE

371 ×1.0

ONCOL

Citations per year, relative to Douglas M. McCarty Douglas M. McCarty (= 1×) peers Cathryn Mah

Countries citing papers authored by Douglas M. McCarty

Since Specialization

Citations

This map shows the geographic impact of Douglas M. McCarty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas M. McCarty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas M. McCarty more than expected).

Fields of papers citing papers by Douglas M. McCarty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas M. McCarty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas M. McCarty. The network helps show where Douglas M. McCarty may publish in the future.

Co-authorship network of co-authors of Douglas M. McCarty

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas M. McCarty. A scholar is included among the top collaborators of Douglas M. McCarty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas M. McCarty. Douglas M. McCarty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chung, Cheng-Han, Vincent P. M. Wingate, Jeffrey W. Pavlicek, et al.. (2023). Production of rAAV by plasmid transfection induces antiviral and inflammatory responses in suspension HEK293 cells. Molecular Therapy — Methods & Clinical Development. 28. 272–283. 28 indexed citations

Muhuri, Manish, David Lévy, Martin Schulz, Douglas M. McCarty, & Guangping Gao. (2022). Durability of transgene expression after rAAV gene therapy. Molecular Therapy. 30(4). 1364–1380. 67 indexed citations

Huey, Devra, et al.. (2021). Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS ONE. 16(2). e0246770–e0246770. 8 indexed citations

Fu, Haiyan, et al.. (2018). Targeting Root Cause by Systemic scAAV9-hIDS Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice. Molecular Therapy — Methods & Clinical Development. 10. 327–340. 16 indexed citations

Fu, Haiyan, et al.. (2017). Differential prevalence of antibodies against adeno-associated virus in healthy children and patients with mucopolysaccharidosis III: perspective for AAV-mediated gene therapy. 1 indexed citations

Fu, Haiyan, et al.. (2017). Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy. PubMed. 28(4). 187–196. 40 indexed citations

Fu, Haiyan, Douglas M. McCarty, Kelly McNally, et al.. (2016). A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Molecular Genetics and Metabolism. 119(3). 239–248. 40 indexed citations

Fu, Haiyan & Douglas M. McCarty. (2016). Crossing the blood–brain-barrier with viral vectors. Current Opinion in Virology. 21. 87–92. 44 indexed citations

Meadows, Aaron S., F. Jason Duncan, Marybeth Camboni, et al.. (2015). A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB. PubMed. 26(4). 228–242. 20 indexed citations

10.

Murrey, Darren, Bartholomew J. Naughton, F. Jason Duncan, et al.. (2014). Feasibility and Safety of Systemic rAAV9-h NAGLU Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in Primates. PubMed. 25(2). 72–84. 83 indexed citations

11.

Murrey, Darren, Bartholomew J. Naughton, F. Jason Duncan, et al.. (2014). Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-distribution and Immunological Assessments in Primates. 776275620–776275620. 6 indexed citations

12.

Pythoud, Catherine, Marc Levivier, Douglas M. McCarty, et al.. (2012). Rapid Transgene Expression in Multiple Precursor Cell Types of Adult Rat Subventricular Zone Mediated by Adeno-Associated Type 1 Vectors. Human Gene Therapy. 23(7). 742–753. 13 indexed citations

13.

Cataldi, Marcela P. & Douglas M. McCarty. (2012). Hairpin-end conformation of adeno-associated virus genome determines interactions with DNA-repair pathways. Gene Therapy. 20(6). 686–693. 16 indexed citations

14.

Fu, Haiyan, Julianne DiRosario, Kang Lu, Joseph Muenzer, & Douglas M. McCarty. (2010). Restoration of central nervous system α‐N‐acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno‐associated viral type 2 vector delivery. The Journal of Gene Medicine. 12(7). 624–633. 34 indexed citations

15.

McCarty, Douglas M., et al.. (2009). Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Therapy. 16(11). 1340–1352. 87 indexed citations

16.

DiRosario, Julianne, Chuansong Wang, Jonathan P. Etter, et al.. (2008). Innate and adaptive immune activation in the brain of MPS IIIB mouse model. Journal of Neuroscience Research. 87(4). 978–990. 81 indexed citations

17.

Hacker, Ulrich, David M. Kofler, Tobias Herold, et al.. (2005). Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. The Journal of Gene Medicine. 7(11). 1429–1438. 51 indexed citations

18.

Fu, Haiyan, Joseph Muenzer, R. Jude Samulski, et al.. (2003). Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Molecular Therapy. 8(6). 911–917. 137 indexed citations

19.

Chen, Hong, et al.. (1999). Oligodendrocyte-specific gene expression in mouse brain: Use of a myelin-forming cell type-specific promoter in an adeno-associated virus. Journal of Neuroscience Research. 55(4). 504–513. 54 indexed citations

20.

Xiao, Xiao, et al.. (1997). New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nature Medicine. 3(11). 1295–1297. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact